$3.17
Price
$752M
Market Cap
—
P/E Ratio
51.6
Forward P/E
$-0.54
EPS (TTM)
—
Dividend Yield
$92M
Cash
$298M
Total Debt
237M
Shares Out
$0.69
$4.18
52-Week Range
Institutional Ownership of ESPERION THERAPEUTICS INC NE
|
Fund / Manager
Click to search
|
Shares | Value | % of Portfolio | Cost Basis | Est. Return |
|---|---|---|---|---|---|
| No funds currently hold this stock. | |||||
Trading Activity for ESPERION THERAPEUTICS INC NE
|
Fund / Manager
Click to search
|
Action | Change | Shares After | Value | Price |
|---|---|---|---|---|---|
| No activity found for this stock. | |||||
Insider Trading for ESPERION THERAPEUTICS INC NE
6 Months Insider Sentiment
Buy $0
Sell $348K
0
Buys
7
Sells
-348K
Net
1
Grants
Largest
$177K
Koenig
$79K
Koenig
$27K
Halladay
| Date |
Insider
Click to search
|
Role
Click to search
|
Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Dec 17, 2025 | Sheldon L. Koenig | President and CEO | SELL | 48.2K | $3.67 | $177K |
| Dec 17, 2025 | Benjamin Halladay | Chief Financial Officer | SELL | 7.3K | $3.67 | $27K |
| Dec 17, 2025 | Benjamin Looker | General Counsel | SELL | 6.5K | $3.67 | $24K |
| Dec 04, 2025 | John B. Harlow Jr. | Chief Commercial Officer | GRANT | 424.5K | — | — |
| Oct 17, 2025 | Benjamin Looker | General Counsel | SELL | 1.2K | $2.62 | $3K |
| Sep 17, 2025 | Benjamin Halladay | Chief Financial Officer | SELL | 7.0K | $2.81 | $20K |
| Sep 17, 2025 | Sheldon L. Koenig | President and CEO | SELL | 28.4K | $2.79 | $79K |
| Sep 17, 2025 | Benjamin Looker | General Counsel | SELL | 6.3K | $2.80 | $18K |